Top 5 Oil Service Stocks To Invest In Right Now

Oil services companies have gotten good at hydraulic fracturing, perhaps too good at it. According to Nabors Industries (NYSE: NBR  ) , fracs per day have increased by 50% in the Haynesville Shale. While that may seem like great news, it could be very frustrating for oil services companies. Let's diagnose why and prescribe a potential solution that may resolve this malaise.

Early symptoms: shooting oneself in the foot
During a panel at the EIA energy conference last month, Southwestern Energy vice president Jim Tramuto�declared that we had reached what he called the second quarter of the oil and gas boom. What he means is that companies once rushed to get a well in the ground just to prevent their leases from expiring. Now that those leases have been established, these companies are now focusing on optimizing their operations to get the most out of each dollar spent.

The one thing you can give the oil and gas industry credit for is that it learns quickly. New rig technology like Nabors' PAce-X rig have allowed pad drilling methods to increase wells per rig by 34% in some of the more "mature" shale plays like the Eagle Ford, Bakken, and Marcellus. Also, the 50% gain in fracs per day mentioned above has come thanks to methods such as zipper fracs, which involves alternating pressure at two wells versus fracking one at a time.

Top 5 Quality Stocks To Buy For 2015: SofTech Inc (SOFT)

SofTech, Inc., incorporated on June 11, 1969,is a provider of engineering software solutions with its ProductCenter PLM (product lifecycle management) technology and its computer-aided design product CADRA offering. On May 24, 2011, the Company sold its Advanced Manufacturing Technology (AMT) product line. In October 2013, SofTech, Inc announced that it has completed the sale of substantially all of the assets of its CADRA product line.

ProductCente

The Company's ProductCenter technology manages the engineering data and electronic files of discrete parts designed in third party design technologies offered primarily by Solidworks, Parametric Technology Corporation (PTC) and Autodesk. ProductCenter is an enterprise, collaborative PLM solution delivering a combination of document management, design integration, configuration control, change management, bill of materials management and integration capability with other enterprise systems. ProductCenter is designed to help companies optimize the product development process. ProductCenter provides for the secure management of product information and allows engineers and the entire design chain to manage, share, modify and track product data and documents throughout the product development lifecycle.

The Company�� ProductCenter supports engineering change management and bill of materials management for automating business processes. ProductCenter also enables integration with other business applications, such as enterprise resource planning (ERP), supply chain management (SCM) and customer relationship management (CRM) for continuous data exchange across the product lifecycle.

CADRA

The Company�� CADRA offering is a drafting and design software package for the professional mechanical engineer. The CADRA family of CAD/CAM products includes CADRA Design Drafting, a mechanical design documentation tool, CADRA NC, a 2 through 5 axis NC programming application, and CADRAWorks with SolidWorks p! roviding for an integrated drawing production system and three dimensional (3D)solid modeler. The CADRA family of products includes a collection of translators and software options.

The Company competes with Autodesk, Dassault, Siemens, and PTC

Advisors' Opinion:

• [By Peter Graham]

  Small cap tech, mobile or cloud computing stocks SofTech, Inc (OTCMKTS: SOFT), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Izea Inc (OTCMKTS: IZEA) have been getting some extra attention lately in various investment newsletters or alerts. That�� because at least one of these stocks appears to be the subject of paid third party promotions while another is the focus of an apparent investor relations campaign. Keeping that in mind, are these three tech orientated stocks going to bring profits to investors and traders or bring out the luddite in them? Here is a closer look:

• [By Peter Graham]

  Small cap stocks New China Global (OTCMKTS: NCGI), RealBiz Media Group Inc (OTCMKTS: RBIZ) and SofTech, Inc (OTCMKTS: SOFT) sank 21.11%, 14.81% and 10.89%, respectively, last Friday. Moreover, two of these three small caps have been the subject of paid promotions or investor relations activities, but this week is the start of a new trading week and anything can happen. So will these three small cap stocks keep sinking? Here is a closer look to help you decide on an investing or trading strategy:

Top 5 Oil Service Stocks To Invest In Right Now: Barclays PLC (II)

Barclays PLC (Barclays) is a global financial services provider engaged in retail banking, credit cards, wholesale banking, investment banking, wealth management and investment management services. The Company�� operations include its overseas offices, subsidiaries and associates. The Company operates in eight segments: UK Retail and Business Banking (UK RBB), Europe Retail and Business Banking (Europe RBB), Africa Retail and Business Banking (Africa RBB), Barclaycard, Barclays Investment Bank, Barclays Corporate Banking, Wealth and Investment Management, and Head Office and Other Operations. Advisors' Opinion:

• [By Todd Sullivan]

  HHC has increased all our ownership percentage through the repurchasing of outstanding warrants.

  From the 13D/A
  On December 31, 2013, certain of the Reporting Persons entered into swaps for the benefit of certain Pershing Square Funds. Under the terms of the swaps, (i) the relevant Pershing Square Funds will be obligated to pay to the bank counterparty any negative price performance of the 5,399,839 notional number of Common Shares subject to the swaps as of the expiration date of such swaps, plus interest rates set forth in the applicable contracts, and (ii) the bank counterparty will be obligated to pay the relevant Pershing Square Funds any positive price performance of the 5,399,839 notional number Common Shares subject to the swaps as of the expiration date of the swaps. During the term of the swaps, cash will be paid by the bank counterparty to the relevant Pershing Square Fund in an amount equal to the amount of notional distributions or dividends paid by the Issuer in respect of such notional number of Common Shares. All balances will be settled in cash. The Pershing Square Funds��counterparties for the swaps include entities related to Citibank, Nomura, Soci茅t茅 G茅n茅rale and UBS. The swaps do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership of any Common Shares that may be referenced in the swap contracts or Common Shares or other securities or financial instruments that may be held from time to time by any counterparty to the contracts.

• [By Holly LaFon]

  Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than original cost. As stated in the current prospectus, the Fund�� Investor Class Share�� annual operating expense ratio (gross) is 1.28%. The Fund�� adviser has contractually agreed to waive a portion of its fee and/or reimburse Fund expenses to limit total annual operating expenses at 1.25%, which is in effect until October 31, 2015. Other share classes may vary. The Fund charges a 2.0% redemption fee on shares redeemed within six months of purchase. For the most recent month-end performance, please call (877)328-9437 or visit the Advisor�� website at www.auxierasset.com. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future.Spring 2014 Market CommentaryAuxier Focus Fund�� Investor Class returned a modest 0.25% for the quarter ended March 31, while Standard and Poor�� 500 Stock Index (S&P) rose 1.81%. The Fund ended the quarter with 70% in U.S. stocks, 16% foreign stocks, 1.7 % bonds and 12.3% cash. Since inception in 1999, the Fund�� equity exposure has averaged 72%. Our stockholdings in the healthcare industry generally gained for the quarter. But many of our multinational and foreign stocks were hurt by the threat of currency repercussions from geopolitical events in Russia and Ukraine. The foreign portion of the Fund is easily the most undervalued. Longer term, we see a very favorable risk/reward potential with our UK and European holdings. Some emerging market companies we follow are the cheapest in over twenty years. In allocating capital, we much prefer the gloom of down to flat markets and the corrective process that tempers exuberance. We remember that one of th

Top 5 Oil Service Stocks To Invest In Right Now: ViroPharma Incorporated(VPHM)

ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; Buccolam, a oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents; and maribavir, an antiviral compound for the treatment o f CMV disease through a license agreement with GlaxoSmithKline. The company?s primary development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; and VP 20621, a non-toxigenic strain of C. difficile. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich?s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.

Advisors' Opinion:

• [By Johanna Bennett]

  Shares of ViroPharma (VPHM) spiked nearly 26% after the rare-disease company said it was being acquired by U.K. biopharmaceutical firm Shire (SHPG). Shire is paying $4.2 billion, or $50 a share, to ViroPharma. Shire�� ADRs rose 0.7%

• [By Sean Williams]

  What: Shares of ViroPharma (NASDAQ: VPHM  ) , a biotechnology company specializing in treating rare diseases, rose as much as 14% after a report from Reuters noted preliminary buyout interest in the company.

Top 5 Oil Service Stocks To Invest In Right Now: DUSA Pharmaceuticals Inc.(DUSA)

DUSA Pharmaceuticals, Inc., a vertically integrated dermatology company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions primarily in the United States, Canada, and Korea. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The company also markets the BLU-U without Levulan for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions; and non-PDT drug products, such as ClindaReach and AVAR products. DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts.

Advisors' Opinion:

• [By CRWE]

  DUSA Pharmaceuticals, Inc.(r) (Nasdaq:DUSA), a dermatology company that is developing and marketing Levulan(r) Photodynamic Therapy (PDT), reported that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 14th Annual Healthcare Conference on Monday, September 10, 2012 at 11:15 a.m. ET at The Waldorf Astoria Hotel in New York City.